I said I would keep my experiment n=1 with SARMS updated for any fellow warriors.
PSA still undetectable:
12/7/2022 PSA <0.1 all liver numbers normal.
Briefly: RP 2015, then 37 treatments of EBRT after PSA started rising shortly after.
Bio recurrence 2019.
May-25-2022 TEST RESULTS: PSA 15.2, T 563, AST HIGH 66, ALT HIGH 83, (To many supplements), Started Lupron (joint,muscle pain, plus fatigue).
cut way back on supplements due to AST, and ALT numbers.
June-23 TEST RESULTS: PSA 0.39 T<12
June-25 Started Osterine 10mg/day (pain gone right away, still tired but not as bad)
July-2 Started Carderine 10 mg/day (energy in abundance)
July-18 Started Nubeqa (No side effects)
July-21 4 days after starting Nubeqa TEST RESULTS: PSA BUMP =2.27 (Die off), T 15, bio T 7, AST HIGH =46, ALT NORMAL 34,HDL LOW=34, chol:HDL ratio GOOD =4.6
Aug-8 PSA 0.75
Oct-19 TEST RESULTS: PSA 0.14, T<5 , AST back to Normal =29, ALT back to Normal =23, HDL back to normal = 50, and Chol/HDL=3.9, Glucose at 73 even eating lots of healthy carbs thanks to Carderine.
Swithed Lupron with Orgovyx.
To my great relief so far is these SARMS are actually not interfering with my treatments, but helping fight the cancer with elimination of side effects, and actually helping my bloodwork.
I will keep updating this post when i get more pertinent test results.
Written by
KocoPr
To view profiles and participate in discussions please or .
Thanks for your comments. It would be nice to be able to tell your MO and say I know you can’t prescribe a non FDA approved drug so please monitor my progress and support me. Don’t judge me as I’m the one in the sinking boat.
What Is MK4541?MK4541 is a relatively new SARM.Despite its newness to the scene, this drug is already making a name for itself in the pharmaceutical world.The most important pharmaceutical benefits of MK 4541 is for men with prostate cancer.The drug is currently in development to treat prostate cancer and also to prevent the risk from developing in the first place.Simply put, MK-4541 gets rid of androgen-independent prostate cells. The drug is designed to induce their death to free men with prostate cancer from these harmful cells.What’s so important about this application of MK 4541 is that most other prostate treatments have seriously negative side effects.For example, most prostate cancer treatments cause the body to become androgen deficient.MK-4541 is capable of treating prostate cancer while maintaining androgen levels and without causing any other side effects.In addition to its benefits and continued development for the treatment of prostate cancer, MK-4541 also features numerous fitness benefits.
For those who are contemplating doing research on SARMs or Carderine, etc. Just be careful of sourcing. Some companies have bogus products. They have no independent lab testing of specific batches, and no reviews on their sites. (i.e Alpha Labs). Was advised Chemyo is generally considered the most reliable for research source.
A friend of mine, not cancer related, obtained medications that were unavailable. He said he contacted a pharmaceutical compounder. I'll have to reach out to him.
oh I agree and I guess I didn’t mean it to criticize. I always look at any articles conflicts of interest. When it comes to SARMS there is a fair amount of negativy but after reading many articles including from nih it pays to dig deeper into the claims. Unfortunately there is scant info on SARMS for PCa and nothing while combining with ADT. I found the best info from the heaviest and more experienced users of SARMS and that is body builders.
To me i find the commercial body building website “moreplatesmoredates to have many good articles including usage, suppliers, making your own liquid SARMS from powder which is what i do.
The review will focus on the rationale for SARM development, the molecular basis of androgen action, the mechanistic basis of tissue selectivity, and potential clinical applications for SARMs.
Selective Androgen Receptor Modulators (SARMs) as Function Promoting Therapies
SummarySARMs hold promise as a new class of function promoting anabolic therapies for a number of clinical indications, including functional limitations associated with aging and chronic disease, frailty, cancer cachexia, and osteoporosis.
INTRODUCTIONSelective Androgen Receptor Modulators (SARMs) are a class of androgen receptor ligands that bind androgen receptor and display tissue-selective activation of androgenic signaling (1, 2). The initial efforts to develop steroidal SARMs, based on modifications of the testosterone molecule, date back to the 1940s. The modern era of nonsteroidal SARMs was unleashed by independent work at Ligand Pharmaceuticals (3–6) and the University of Tennessee (7, 8). The scientists at Ligand Pharmaceuticals were the first to develop a series of cyclic quinolinones that had anabolic activity on the skeletal muscle and some degree of tissue selectivity (3, 4, 9–13). The discovery by Dalton and Miller that aryl propionamides with structural similarities to bicalutamide and hydroxyflutamide could activate AR-dependent transcriptional activity provided the early lead for the development of diaryl propionamide class of SARMs (7, 8). The decade since these early efforts has witnessed the emergence of a large number of nonsteroidal SARMs from virtually all the major pharmaceutical companies (2).
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Oncologist gave bad news about the cancer
Liver problems with Zytiga 
I have doubts from PA that Zytiga is working
PSA Question
My COC Implementation Perhaps Positive
